Galmed Pharmaceuticals Third Quarter 2015 Conference Call and Webcast Scheduled for November 9, 2015

Press Releases |

TEL AVIV, Israel, Nov. 2, 2015 -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it will host a conference call and webcast on Monday, November 9, 2015 to discuss results for the period ended September 30, 2015 and to provide an update on current developments with respect to its clinical program for Aramchol.

 

Conference Call & Webcast

Monday, November 9, 2015, 8:30 am Eastern Time / 5:30 am Pacific Time

Participant Dial-In Numbers:

 

Toll-Free:                              

+1-888-359-3624

Toll/International:                 

+1-719-785-1753

Conference ID:          

1521094

Webcast:                            

http://galmedpharma.investorroom.com/events-and-presentations

   

Replay, available until November 23, 2015

Replay Dial-In Numbers:



 

Toll-Free:                              

+1-877-870-5176

Toll/International:                     

+1-858-384-5517

Passcode:                                

1521094

 

About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs.  Galmed believes that its product candidate, Aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need.

Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Galmed's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission, or the SEC, on March 31, 2015, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
GLMD Galmed Pharmaceuticals Ltd. 6.02 0.00 0.00 14,878 Trade

Comments

Emerging Growth

DynaCERT Inc.

DynaCERT Inc is engaged in the assembling, distributing and installation of a patent pending transportable hydrogen generator after-market product, for use in the heavy tractor-trailer industry and into large stationary…

Private Markets

Mesa-Marshall 2 Well Project

MESA Resources ("MESA") is sponsoring the development of the two well direct drilling project -- "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development of…

GoCoin

Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…